Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimedat Bioequivalence Study (ODT vs. Tablets)
NCT07421011Phase 1Recruiting
- Sponsor
- Valenta Pharm
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of trimebutine in irritable bowel syndrome (IBS), gallstone disease, gastroesophageal reflux disease (GERD) and 2 more (2 arms), sponsored by Valenta Pharm. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 3 more. Started Nov 2025; status: recruiting.
02
Drugs
trimebutine
03
Conditions
irritable bowel syndrome (IBS)gallstone diseasegastroesophageal reflux disease (GERD)biliary dyskinesiapostcholecystectomy syndrome (PCS)
Beyond the preview
Go deeper on NCT07421011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07421011.